1	10A NCAC 41A	A .0101 is proposed for amendment under temporary procedures as follows:			
2					
3		CHAPTER 41 - EPIDEMIOLOGY HEALTH			
4 5		SUBCHAPTER 41A - COMMUNICABLE DISEASE CONTROL			
6		SUBCHAFTER 41A - COMMUNICABLE DISEASE CONTROL			
7	SECTION .0100 - COMMUNICABLE DISEASE CONTROL				
8					
9	10A NCAC 41.	A .0101 REPORTABLE DISEASES AND CONDITIONS			
10	(a) The follow	ing named diseases and conditions are declared to be dangerous to the public health and are hereby			
11	made reportable	e within the time period specified after the disease or condition is reasonably suspected to exist:			
12	(1)	acquired immune deficiency syndrome (AIDS) - 24 hours;			
13	(2)	anthrax - immediately;			
14	(3)	botulism - immediately;			
15	(4)	brucellosis - 7 days;			
16	(5)	campylobacter infection - 24 hours;			
17	(6)	Candida auris - 24 hours;			
18	(7)	Carbapenem-Resistant Enterobacteriaceae (CRE) – 24 hours;			
19	(8)	chancroid - 24 hours;			
20	(9)	chikungunya virus infection - 24 hours;			
21	(10)	chlamydial infection (laboratory confirmed) - 7 days;			
22	(11)	cholera - 24 hours;			
23	(12)	Creutzfeldt-Jakob disease – 7 days;			
24	(13)	cryptosporidiosis – 24 hours;			
25	(14)	cyclosporiasis – 24 hours;			
26	(15)	dengue - 7 days;			
27	(16)	diphtheria - 24 hours;			
28	(17)	Escherichia coli, shiga toxin-producing - 24 hours;			
29	(18)	ehrlichiosis – 7 days;			
30	(19)	encephalitis, arboviral - 7 days;			
31	(20)	foodborne disease, including Clostridium perfringens, staphylococcal, Bacillus cereus, and other			
32		and unknown causes - 24 hours;			
33	(21)	gonorrhea - 24 hours;			
34	(22)	granuloma inguinale - 24 hours;			
35	(23)	Haemophilus influenzae, invasive disease - 24 hours;			

```
1
               (24)
                        Hantavirus infection – 7 days;
 2
                (25)
                        Hemolytic-uremic syndrome – 24 hours;
 3
                (26)
                        Hemorrhagic fever virus infection – immediately;
 4
                (27)
                        hepatitis A - 24 hours;
 5
                (28)
                        hepatitis B - 24 hours;
                        hepatitis B carriage - 7 days;
 6
                (29)
 7
                (30)
                        hepatitis C, acute – 7 days;
 8
                (31)
                        human immunodeficiency virus (HIV) infection confirmed - 24 hours;
 9
                (32)
                         influenza virus infection causing death – 24 hours;
10
                (33)
                         legionellosis - 7 days;
                        leprosy - 7 days;
11
                (34)
12
                (35)
                         leptospirosis - 7 days;
13
                (36)
                        listeriosis – 24 hours;
                        Lyme disease - 7 days;
14
                (37)
15
                (38)
                        Lymphogranuloma venereum - 7 days;
                (39)
                        malaria - 7 days;
16
17
                (40)
                        measles (rubeola) - 24 hours;
18
                (41)
                        meningitis, pneumococcal - 7 days;
19
                (42)
                        meningococcal disease - 24 hours;
20
                (43)
                         Middle East respiratory syndrome (MERS) - 24 hours;
21
                (44)
                        monkeypox - 24 hours;
22
                        mumps - 7 days;
                (45)
23
                (46)
                        nongonococcal urethritis - 7 days;
24
                        novel coronavirus infection – immediately;
                (47)
25
                (48)(47) novel influenza virus infection – immediately;
26
                (49)(48) plague - immediately;
27
                (50)<del>(49)</del> paralytic poliomyelitis - 24 hours;
28
                (51)(50) pelvic inflammatory disease – 7 days;
29
                (52)(51) psittacosis - 7 days;
30
                (53)(52) Q fever - 7 days;
31
                (54)(53) rabies, human - 24 hours;
                (55)<del>(54)</del> Rocky Mountain spotted fever - 7 days;
32
33
                (56)(55) rubella - 24 hours;
34
                (57)<del>(56)</del> rubella congenital syndrome - 7 days;
```

```
1
                (58)<del>(57)</del> salmonellosis - 24 hours;
 2
                (59)(58) severe acute respiratory syndrome (SARS) – 24 hours;
 3
                (60)(59) shigellosis - 24 hours;
 4
                (61)(60) smallpox - immediately;
 5
                (62)(61) Staphylococcus aureus with reduced susceptibility to vancomycin – 24 hours;
 6
                (63)<del>(62)</del> streptococcal infection, Group A, invasive disease - 7 days;
 7
                (64)(63) syphilis - 24 hours;
 8
                (65)(64) tetanus - 7 days;
 9
                (66)<del>(65)</del> toxic shock syndrome - 7 days;
10
                (67)<del>(66)</del> trichinosis - 7 days;
11
                (68)(67) tuberculosis - 24 hours;
12
                (69)<del>(68)</del> tularemia – immediately;
13
                (70)(69) typhoid - 24 hours;
14
                (71)(70) typhoid carriage (Salmonella typhi) - 7 days;
15
                (72)<del>(71)</del> typhus, epidemic (louse-borne) - 7 days;
16
                (73)(72) vaccinia – 24 hours;
17
                (74)(73) vibrio infection (other than cholera) – 24 hours;
18
                (75)\frac{(74)}{(74)} whooping cough – 24 hours; and
19
                (76)\frac{(75)}{(75)} yellow fever - 7 days.
20
       (b) For purposes of reporting, "confirmed human immunodeficiency virus (HIV) infection" is defined as a positive
21
       virus culture, repeatedly reactive EIA antibody test confirmed by western blot or indirect immunofluorescent antibody
22
       test, positive nucleic acid detection (NAT) test, or other confirmed testing method approved by the Director of the
23
       State Public Health Laboratory conducted on or after February 1, 1990. In selecting additional tests for approval, the
24
       Director of the State Public Health Laboratory shall consider whether such tests have been approved by the federal
25
       Food and Drug Administration, recommended by the federal Centers for Disease Control and Prevention, and
26
       endorsed by the Association of Public Health Laboratories.
27
       (c) In addition to the laboratory reports for Mycobacterium tuberculosis, Neisseria gonorrhoeae, and syphilis specified
28
       in G.S. 130A-139, laboratories shall report using electronic laboratory reporting (ELR), secure telecommunication, or
29
       paper reports.
30
                (1)
                         Isolation or other specific identification of the following organisms or their products from human
31
                         clinical specimens:
32
                         (A)
                                   Any hantavirus or hemorrhagic fever virus.
33
                         (B)
                                   Arthropod-borne virus (any type).
34
                         (C)
                                   Bacillus anthracis, the cause of anthrax.
35
                         (D)
                                   Bordetella pertussis, the cause of whooping cough (pertussis).
36
                         (E)
                                   Borrelia burgdorferi, the cause of Lyme disease (confirmed tests).
```

1	(F) Brucella spp., the causes of brucellosis.
2	(G) Campylobacter spp., the causes of campylobacteriosis.
3	(H) Candida auris.
4	(I) Carbapenem-Resistant Enterobacteriaceae (CRE).
5	(J) Chlamydia trachomatis, the cause of genital chlamydial infection, conjunctivitis (adult and
6	newborn) and pneumonia of newborns.
7	(K) Clostridium botulinum, a cause of botulism.
8	(L) Clostridium tetani, the cause of tetanus.
9	(M) Coronavirus, novel human strain.
10	(N)(M) Corynebacterium diphtheriae, the cause of diphtheria.
11	(O)(N) Coxiella burnetii, the cause of Q fever.
12	(P)(O) Cryptosporidium parvum, the cause of human cryptosporidiosis.
13	(Q)(P) Cyclospora cayetanesis, the cause of cyclosporiasis.
14	(R)(Q) Ehrlichia spp., the causes of ehrlichiosis.
15	(S)(R) Shiga toxin-producing Escherichia coli, a cause of hemorrhagic colitis, hemolytic uremic
16	syndrome, and thrombotic thrombocytopenic purpura.
17	(T)(S) Francisella tularensis, the cause of tularemia.
18	(U)(T) Hepatitis B virus or any component thereof, such as hepatitis B surface antigen.
19	(V)(U) Human Immunodeficiency Virus, the cause of AIDS.
20	(W)(V) Legionella spp., the causes of legionellosis.
21	(X)(W) Leptospira spp., the causes of leptospirosis.
22	(Y)(X) Listeria monocytogenes, the cause of listeriosis.
23	(Z)(Y) Middle East respiratory syndrome virus.
24	(AA)(Z) Monkeypox.
25	(BB)(AA) Mycobacterium leprae, the cause of leprosy.
26	(CC)(BB) Plasmodium falciparum, P. malariae, P. ovale, and P. vivax, the causes of malaria in
27	humans.
28	(DD)(CC) Poliovirus (any), the cause of poliomyelitis.
29	(EE)(DD) Rabies virus.
30	(FF)(EE) Rickettsia rickettsii, the cause of Rocky Mountain spotted fever.
31	(GG)(FF) Rubella virus.
32	(HH)(GG) Salmonella spp., the causes of salmonellosis.
33	(II)(HH) Shigella spp., the causes of shigellosis.
34	(JJ)(II) Smallpox virus, the cause of smallpox.
35	(KK)(JJ)Staphylococcus aureus with reduced susceptibility to vanomycin.
36	(LL)(KK) Trichinella spiralis, the cause of trichinosis.
37	(MM)(LL) Vaccinia virus.

1		(NN)(MM) Vibrio spp., the causes of cholera and other vibrioses.					
2		(OO)(NN) Yellow fever virus.					
3		(PP)(OO) Yersinia pestis, the cause of plague.					
4	(2)	Isolation or other specific identification of the following organisms from normally sterile human					
5		body sites:					
6		(A)	Group	A Streptococcus pyogenes (group A streptococci).			
7		(B)	Haemo	philus influenzae, serotype b.			
8		(C)	Neisser	ia meningitidis, the cause of meningococcal disease.			
9	(3)	Positive serologic test results, as specified, for the following infections:					
10		(A)	Fourfol	d or greater changes or equivalent changes in serum antibody titers to:			
11			(i)	Any arthropod-borne viruses associated with meningitis or encephalitis in a			
12				human.			
13			(ii)	Any hantavirus or hemorrhagic fever virus.			
14			(iii)	Chlamydia psittaci, the cause of psittacosis.			
15			(iv)	Coxiella burnetii, the cause of Q fever.			
16			(v)	Dengue virus.			
17			(vi)	Ehrlichia spp., the causes of ehrlichiosis.			
18			(vii)	Measles (rubeola) virus.			
19			(viii)	Mumps virus.			
20			(ix)	Rickettsia rickettsii, the cause of Rocky Mountain spotted fever.			
21			(x)	Rubella virus.			
22			(xi)	Yellow fever virus.			
23		(B)	The pre	esence of IgM serum antibodies to:			
24			(i) Chla	amydia psittaci.			
25			(ii) Hep	patitis A virus.			
26			(iii) He	patitis B virus core antigen.			
27			(iv) Ru	bella virus.			
28			(v) Rub	peola (measles) virus.			
29			(vi) Ye	llow fever virus.			
30	(4)	Laboratory results from tests to determine the absolute and relative counts for the T-helper (CD4)					
31		subset of lymphocytes and all results from tests to determine HIV viral load.					
32	(5)	Identification of CRE from a clinical specimen associated with either infection or colonization,					
33		includi	ng all sus	ceptibility results and all phenotypic or molecular test results.			
34	(d) Laboratories utilizing electronic laboratory reporting (ELR) shall report in addition to those listed under Paragraph						
35	(c) of this Rule:						
36	(1)	All pos	sitive labo	oratory results from tests used to diagnosis chronic Hepatitis C Infection, including			
37		the foll	lowing:				

1		(A) Hepatitis C virus antibody tests (including the test specific signal to cut-off (s/c) ratio);			
2		(B) Hepatitis C nucleic acid tests;			
3		(C) Hepatitis C antigen(s) tests; and			
4		(D) Hepatitis C genotypic tests.			
5	(2)	All HIV genotypic test results, including when available:			
6		(A) The entire nucleotide sequence; or			
7		(B) The pol region sequence (including all regions: protease (PR)/reverse transcriptase (RT)			
8		and integrase (INI) genes, if available).			
9	(e) For the purp	poses of reporting, Carbapenem-Resistant Enterobacteriaceae (CRE) are defined as:			
10	(1)	Enterobacter spp, E.coli or Klebsiella spp positive for a known carbapenemase resistance			
11		mechanism or positive on a phenotypic test for carbapenemase production; or			
12	(2)	Enterobacter spp, E.coli or Klebsiella spp resistant to any carbapenem in the absence of			
13		carbapenemase resistance mechanism testing or phenotypic testing for carbapenemase production.			
14					
15	History Note:	Authority G.S. 130A-134; 130A-135; 130A-139; 130A-141;			
16		Amended Eff. October 1, 1994; February 1, 1990;			
17		Temporary Amendment Eff. July 1, 1997;			
18		Amended Eff. August 1, 1998;			
19		Temporary Amendment Eff. February 13, 2003; October 1, 2002; February 18, 2002; June 1, 2001;			
20		Amended Eff. April 1, 2003;			
21		Temporary Amendment Eff. November 1, 2003; May 16, 2003;			
22		Amended Eff. January 1, 2005; April 1, 2004;			
23		Temporary Amendment Eff. June 1, 2006;			
24		Amended Eff. April 1, 2008; November 1, 2007; October 1, 2006;			
25		Temporary Amendment Eff. January 1, 2010;			
26		Temporary Amendment Expired September 11, 2011;			
27		Amended Eff. July 1, 2013;			
28		Temporary Amendment Eff. December 2, 2014;			
29		Amended Eff. October 1, 2015;			
30		Emergency Amendment Eff. March 1, 2016;			
31		Temporary Amendment Eff. July 1, 2016;			
32		Amended Eff. January 1, 2018; October 1, 2016;			
33		Pursuant to G.S. 150B-21.3A, rule is necessary without substantive public interest Eff. January 9,			
34		2018;			
35		Amended Eff. October 1, 2018.			
36					

37